In vivo experiments using APP/PS1 and 3xTg-AD transgenic mouse models revealed that BEOV administration significantly reduced Aβ deposits, improved glucose metabolism, and prevented tau phosphorylation—key hallmarks of AD pathology. The gene discussed is APP; the disease is Alzheimer disease.